[{"orgOrder":0,"company":"St. Jude Children","sponsor":"CURE Childhood Cancer, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Oncology","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ CURE Childhood Cancer, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children \/ CURE Childhood Cancer, Inc."},{"orgOrder":0,"company":"Institute for Clinical and Experimental Medicine","sponsor":"Charite University, Berlin, Germany | Miltenyi Biomedicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CZECH REPUBLIC","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Immunology","graph2":"Undisclosed","graph3":"Institute for Clinical and Experimental Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute for Clinical and Experimental Medicine \/ Charite University, Berlin, Germany | Miltenyi Biomedicine","highestDevelopmentStatusID":"1","companyTruncated":"Institute for Clinical and Experimental Medicine \/ Charite University, Berlin, Germany | Miltenyi Biomedicine"},{"orgOrder":0,"company":"Shanghai Zhangjiang Biotechnology Limited Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Zhangjiang Biotechnology Limited Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Zhangjiang Biotechnology Limited Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Zhangjiang Biotechnology Limited Company \/ Undisclosed"},{"orgOrder":0,"company":"University of Ulm","sponsor":"Technical University of Munich | WiSP Wissenschaftlicher Service Pharma GmbH | German CLL Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"University of Ulm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulm \/ Technical University of Munich | WiSP Wissenschaftlicher Service Pharma GmbH | German CLL Study Group","highestDevelopmentStatusID":"8","companyTruncated":"University of Ulm \/ Technical University of Munich | WiSP Wissenschaftlicher Service Pharma GmbH | German CLL Study Group"},{"orgOrder":0,"company":"University Hospital Muenster","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"University Hospital Muenster","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital Muenster \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Muenster \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"National Health Service, UK | Pfizer Inc | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ National Health Service, UK | Pfizer Inc | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"9","companyTruncated":"University of Oxford \/ National Health Service, UK | Pfizer Inc | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Chicago \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"University of Chicago \/ Sanofi"},{"orgOrder":0,"company":"Northwestern University","sponsor":"GSK | National Comprehensive Cancer Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ GSK | National Comprehensive Cancer Network","highestDevelopmentStatusID":"8","companyTruncated":"Northwestern University \/ GSK | National Comprehensive Cancer Network"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase III","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of British Columbia \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"University of British Columbia \/ Sanofi"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johns Hopkins University \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Johns Hopkins University \/ Sanofi"},{"orgOrder":0,"company":"Boston Children's Hospital","sponsor":"Dana-Farber Cancer Institute | Children's Hospital Medical Center, Cincinnati | Children's Hospital Los Angeles | Fred Hutch\/University of Washington\/Seattle Children's Cancer Consortium | Baylor College of Medicine | Children's Hospital of Philadelphia |","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Boston Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Children's Hospital \/ Dana-Farber Cancer Institute | Children's Hospital Medical Center, Cincinnati | Children's Hospital Los Angeles | Fred Hutch\/University of Washington\/Seattle Children's Cancer Consortium | Baylor College of Medicine | Children's Hospital of Philadelphia |","highestDevelopmentStatusID":"8","companyTruncated":"Boston Children's Hospital \/ Dana-Farber Cancer Institute | Children's Hospital Medical Center, Cincinnati | Children's Hospital Los Angeles | Fred Hutch\/University of Washington\/Seattle Children's Cancer Consortium | Baylor College of Medicine | Children's Hospital of Philadelphia |"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Central Texas Neurology Consultants","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase III","graph3":"Central Texas Neurology Consultants","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Central Texas Neurology Consultants \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Central Texas Neurology Consultants \/ Sanofi"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Sanofi"},{"orgOrder":0,"company":"Seah Lim M.D.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase II","graph3":"Seah Lim M.D.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seah Lim M.D. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seah Lim M.D. \/ Undisclosed"},{"orgOrder":0,"company":"Cellectis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Undisclosed"},{"orgOrder":0,"company":"Cellectis","sponsor":"EIB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ EIB","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ EIB"},{"orgOrder":0,"company":"Cellectis","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ European Investment Bank"},{"orgOrder":0,"company":"Cellectis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2021","type":"Partnership","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Cellectis","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Cellectis"}]
Find Clinical Drug Pipeline Developments & Deals for Alemtuzumab
Details :
In Cellectis sponsored trials, alemtuzumab is currently used as part of the lymphodepleting regimen for UCART22 in the BALLI-01 clinical trial in relapsed/refractory ALL, and for UCART123 in the AMELI-01 clinical trial in relapsed/refractory AML, but not...
Details :
Alemtuzumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis.
Details :
Alemtuzumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.
Details :
Alemtuzumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.
Details :
The Company plans to use the proceeds of Tranche C towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22 and UCART20x22.
Details :
UCART22 is an allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of R/R B-ALL, in combination with alemtuzumab.
Details :
UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Details :
The Company plans to use the proceeds towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, UCART123 and UCARTCS1.
Details :
Alemtuzumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Multiple Sclerosis.
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
